MX2018004257A - Antagonista de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos. - Google Patents

Antagonista de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.

Info

Publication number
MX2018004257A
MX2018004257A MX2018004257A MX2018004257A MX2018004257A MX 2018004257 A MX2018004257 A MX 2018004257A MX 2018004257 A MX2018004257 A MX 2018004257A MX 2018004257 A MX2018004257 A MX 2018004257A MX 2018004257 A MX2018004257 A MX 2018004257A
Authority
MX
Mexico
Prior art keywords
nr2b antagonists
formula
selective nr2b
selective
compounds
Prior art date
Application number
MX2018004257A
Other languages
English (en)
Inventor
Islam Imadul
E Macor John
Thangathirupathy Srinivasan
Sankara Warrier Jayakumar
Cheruku Srinivas
Shetty Poornima
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of MX2018004257A publication Critical patent/MX2018004257A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción proporciona compuestos de Fórmula (I) y sales farmacéuticamente aceptables de los mismos. Los compuestos de Fórmula (I) son ligandos para el receptor NR2B N-Metil-D-aspartato (NMD A) y por lo tanto los hacen útiles para el tratamiento de diversos trastornos del sistema nervioso central.
MX2018004257A 2015-10-14 2016-10-13 Antagonista de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos. MX2018004257A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3309DE2015 2015-10-14
PCT/US2016/056716 WO2017066368A1 (en) 2015-10-14 2016-10-13 Selective nr2b antagonists

Publications (1)

Publication Number Publication Date
MX2018004257A true MX2018004257A (es) 2018-05-16

Family

ID=57208377

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004257A MX2018004257A (es) 2015-10-14 2016-10-13 Antagonista de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.

Country Status (13)

Country Link
US (2) US10501451B2 (es)
EP (1) EP3362447B1 (es)
JP (1) JP6843853B2 (es)
KR (1) KR20180064507A (es)
CN (1) CN108368101B (es)
AU (1) AU2016340239A1 (es)
BR (1) BR112018007181A2 (es)
CA (1) CA3001894A1 (es)
EA (1) EA201890764A1 (es)
ES (1) ES2822830T3 (es)
IL (1) IL258611A (es)
MX (1) MX2018004257A (es)
WO (1) WO2017066368A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016340237A1 (en) * 2015-10-14 2018-05-31 Bristol-Myers Squibb Company Selective NR2B antagonists
EP3867245B1 (en) * 2018-10-17 2022-12-07 Boehringer Ingelheim International GmbH 4-pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament
EP3866854B1 (en) * 2018-10-17 2022-08-10 Boehringer Ingelheim International GmbH 4-pyridinylmethyl-morpholine derivatives and the use thereof as medicament
PE20211278A1 (es) * 2018-10-17 2021-07-19 Boehringer Ingelheim Int Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento
AU2021390209A1 (en) * 2020-12-04 2023-06-22 Novartis Ag Dosage regimen for a nr2b-nmda receptor nam for the treatment of depression
CN113620896A (zh) * 2021-08-31 2021-11-09 青岛科技大学 2-(2-氯苯基)甲基-4,4-二甲基-3-异恶唑酮的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US7022728B2 (en) 2001-03-09 2006-04-04 Abbott Laboratories Benzimidazoles that are useful in treating male sexual dysfunction
JPWO2003035641A1 (ja) 2001-10-22 2005-02-10 塩野義製薬株式会社 新規カルバモイルピロリドン誘導体
PL1648882T3 (pl) 2003-06-04 2008-12-31 Merck & Co Inc 3-Fluoro-piperydyny jako antagoniści NMDA/NR2B
WO2005035523A1 (en) 2003-10-08 2005-04-21 Pfizer Japan Inc. Fused lactam compounds
US20070185168A1 (en) * 2004-04-07 2007-08-09 Takai Haruki S Piperidine derivatives
JPWO2006137465A1 (ja) * 2005-06-24 2009-01-22 塩野義製薬株式会社 含窒素複素環誘導体
EP2520567A3 (en) 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
US8420680B2 (en) 2007-06-29 2013-04-16 Emory University NMDA receptor antagonists for neuroprotection
JP2009067784A (ja) * 2007-08-21 2009-04-02 Shionogi & Co Ltd 環式基で置換された含窒素複素環誘導体を含有する鎮痛剤
US9101612B2 (en) * 2010-02-11 2015-08-11 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
US9221796B2 (en) 2014-01-09 2015-12-29 Bristol-Myers Squibb Company Selective NR2B antagonists
US9187506B2 (en) 2014-01-09 2015-11-17 Bristol-Myers Squibb Company (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders

Also Published As

Publication number Publication date
CN108368101B (zh) 2022-03-15
US10954225B2 (en) 2021-03-23
ES2822830T3 (es) 2021-05-05
US20200115370A1 (en) 2020-04-16
JP6843853B2 (ja) 2021-03-17
JP2018530582A (ja) 2018-10-18
WO2017066368A1 (en) 2017-04-20
CA3001894A1 (en) 2017-04-20
CN108368101A (zh) 2018-08-03
AU2016340239A1 (en) 2018-05-31
US20180312495A1 (en) 2018-11-01
EP3362447A1 (en) 2018-08-22
KR20180064507A (ko) 2018-06-14
US10501451B2 (en) 2019-12-10
EP3362447B1 (en) 2020-08-26
IL258611A (en) 2018-06-28
BR112018007181A2 (pt) 2018-10-16
EA201890764A1 (ru) 2018-09-28

Similar Documents

Publication Publication Date Title
MX2018004257A (es) Antagonista de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.
CY1121675T1 (el) Διαμορφωτες υποδοχεων nmdα σπeipο-λακταμης και χρησεις αυτων
MX2021009830A (es) Metodos para el tratamiento de trastornos del movimiento involuntario anormal.
NZ737399A (en) Ccr2 modulators
EA201992474A3 (ru) Агонисты 5ht для лечения нарушений
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
TW201613859A (en) Analogs of PRIDOPIDINE, their preparation and use
MX2017014192A (es) Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.
TN2016000263A1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
EA033197B1 (ru) Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b
JO3654B1 (ar) مركبات ازا بنزيميدازول واستخدامها كمعدلات للمستقبلات ذات النمط الإمبائي (ampa)
TW201713341A (en) Compositions and methods of treating a neurodegenerative disease
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
MX2017013877A (es) Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
MX2020011668A (es) Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.
NZ730816A (en) Quinoline carboxamides for use in the treatment of multiple myeloma
MX2015015073A (es) Sintesis de 3-(5-amino-2-metil-4-oxoquinazolin-3(4h)-il)piperidin- 2,6-diona.
MX2016008898A (es) Antagonistas selectivos de nr2b.
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
PH12016501625A1 (en) Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
PH12016501483A1 (en) P-substituted asymmetric ureas and medical uses thereof
MX369451B (es) Formas cristalinas de compuestos basados en 1, 8- naftiridin-4(h)-ona particulares y su uso en el tratamiento de ansiedad y condiciones relacionadas.
MX2018004256A (es) Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.
MX2015015290A (es) Compuestos furanona como inhibidores de quinasa.